98%
921
2 minutes
20
Metabolism in vivo turns small molecules (e.g., drugs) into metabolites (new molecules), which brings unexpected safety issues in drug development. However, it is costly to determine metabolites by biological assays. Recent computational methods provide new promising approaches by predicting possible metabolites. Rule-based methods utilize predefined reaction-derived rules to infer metabolites. However, they are powerless to new metabolic reaction patterns. In contrast, rule-free methods leverage sequence-to-sequence machine translation to generate metabolites. Nevertheless, they are insufficient to characterize molecule structures, and bear weak interpretability. To address these issues in rule-free methods, this manuscript proposes a novel metabolism type-aware graph generative framework (MTGGF) for molecular metabolite prediction. It contains a two-stage learning process, including a pre-training on a large general chemical reaction dataset, and a fine-tuning on three smaller type-specific metabolic reaction datasets. Its core, an elaborate graph-to-graph generative model, treats both atoms and bonds as bipartite vertices, and molecules as bipartite graphs, such that it can embed rich information of molecule structures and ensure the integrity of generated metabolite structures. The comparison with state-of-the-art methods demonstrates its superiority. Furthermore, the ablation study validates the contributions of its two graph encoding components and its reaction-type-specific fine-tuning models. More importantly, based on interactive attention between a molecule and its metabolites, the case studies on five approved drugs reveal that there exist crucial substructures specific to metabolism types. It is anticipated that this framework can boost the risk evaluation of drug metabolites. The codes are available at https://github.com/zpczaizheli/Metabolite .
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12539-024-00681-4 | DOI Listing |
Interdiscip Sci
September 2025
School of Life Sciences, Northwestern Polytechnical University, Xi'an, 710072, China.
Metabolism in vivo turns small molecules (e.g., drugs) into metabolites (new molecules), which brings unexpected safety issues in drug development.
View Article and Find Full Text PDFNew Phytol
January 2025
Center for Applied Genetic Technologies, University of Georgia, Athens, 30602, GA, USA.
In plants, the biosynthetic pathways of some specialized metabolites are partitioned into specialized or rare cell types, as exemplified by the monoterpenoid indole alkaloid (MIA) pathway of Catharanthus roseus (Madagascar Periwinkle), the source of the anticancer compounds vinblastine and vincristine. In the leaf, the C. roseus MIA biosynthetic pathway is partitioned into three cell types with the final known steps of the pathway expressed in the rare cell type termed idioblast.
View Article and Find Full Text PDFNat Commun
September 2024
Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Unsolved Mendelian cases often lack obvious pathogenic coding variants, suggesting potential non-coding etiologies. Here, we present a single cell multi-omic framework integrating embryonic mouse chromatin accessibility, histone modification, and gene expression assays to discover cranial motor neuron (cMN) cis-regulatory elements and subsequently nominate candidate non-coding variants in the congenital cranial dysinnervation disorders (CCDDs), a set of Mendelian disorders altering cMN development. We generate single cell epigenomic profiles for ~86,000 cMNs and related cell types, identifying ~250,000 accessible regulatory elements with cognate gene predictions for ~145,000 putative enhancers.
View Article and Find Full Text PDFEBioMedicine
August 2024
Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Bioinformatics Interdepartmental Program, UCLA, Los Angeles, CA, USA; Institute for Precision Health, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address:
Nat Commun
January 2023
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.